Martin Hutchings, MD, PhD and Robert Marcus, MA, FRCP, FRCPath

In this episode, “Next Steps for Indolent B-Cell Lymphomas”, Martin Hutchings, MD, PhD and Robert Marcus, MA, FRCP, FRCPath consider the best path forward.

Most patients with follicular lymphoma (FL) do very well on standard therapy. However, it is important to have the tools to identify those who will progress early so they can be offered different therapy at the outset. It is thought that this subset may derive the greatest benefit from clinical trials of novel agents or even doublet/triplet regimens to overcome resistance. 

Share this story, choose your platform!